DJIA 17,840.79 121.79 0.69%
NASDAQ 4,721.95 20.08 0.43%
S&P 500 2,064.94 12.19 0.59%
market minute promo

Roche Holding Ltd. (ADR) (NASDAQOTH: RHHBY)

37.46 -0.23 (-0.60%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

RHHBY $37.46 -0.60%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $37.56
Previous Close $37.68
Daily Range $37.43 - $37.61
52-Week Range $32.68 - $38.71
Market Cap $210.5B
P/E Ratio 0.00
Dividend (Yield) $0.00 (2.4%)
Volume 123,597
Average Daily Volume 991,079
Current FY EPS $1.99





Roche Holding Ltd. (ADR) (RHHBY) Description


News & Commentary Rss Feed

This High-Yield Dividend Stock Screams Danger

This high-yield dividend stock may be paying out north of 7%, but its long-term outlook might have investors wisely running in the opposite direction.

Why Shareholders of Organovo Holdings Inc Have Been Waiting For This Day

This 3D bioprinting company finally has a product on the market.

Why Novartis and Regeneron Care About This Tiny Biotech Stock

Ophthotech's Fovista may tip the scale in favor of either Novartis' Lucentis or Regeneron's Eylea.

3 Drugs That Make Gilead Sciences' Harvoni Look Cheap

Cancer drugs from Bristol-Myers Squibb, Novartis, and Roche come with higher price tags than Gilead Sciences hepatitis C drug Harvoni.

Pharmacyclics, Inc.'s Imbruvica Holds Its Own Against Gilead Sciences, Inc.'s Zydelig

Pharmacyclics third-quarter results showed impressive sales growth for Imbruvica, a drug that competes against Gilead's Zydelig.

Why Exelixis, Inc. Stock Pushed 11% Higher in October

Exelixis was one of the best biotech stocks in October. Find out what sent its shares higher by 11% and whether or not the good times will keep rolling for this small-cap biotech stock.

Why ImmunoGen, Inc. Stock Plunged 13% in October

ImmunoGen is among biotech's worst stocks in October after the company reports weaker-than-expected third quarter results. Find out if a rebound is in the cards.

Why Pacific Biosciences of California Stock Skyrocketed 34% in October

PacBio was among the best performing healthcare stocks in October. Find out what lit a fire under its shares.

Pacific Biosciences of California Earnings Rocket Higher on Roche Deal

What investors need to know about Pacific Biosciences' third quarter performance.

Could Inovio Pharmaceuticals Inc. Be Running Out of Money?

A biotech stock running out of money is a very real concern for healthcare investors. With $317.3 million in an accumulated deficit since inception, does Inovio have enough cash to survive?.

See More RHHBY News...

RHHBY's Top Competitors

RHHBY $37.46 (-0.60%)
Current stock: RHHBY
JNJ $107.89 (0.38%)
Current stock: JNJ
NVS $94.82 (-0.47%)
Current stock: NVS
GSK $46.58 (0.43%)
Current stock: GSK